Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | SVP, Products Business | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 156,098 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 3,000 · Balance 156,098 F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.52 to $6.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.52 to $6.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 13:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,000 | $6.53 | $19,590.00 |
DisclosureSEC source: 0001961994-26-000029 · wk-form4_1791206183.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,098 F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.52 to $6.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,000 | $8.40 | $25,200.00 |
DisclosureSEC source: 0001961994-26-000024 · wk-form4_1783011439.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,098 F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 19:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 694 | $8.00 | $5,552.00 |
DisclosureSEC source: 0001961994-26-000021 · wk-form4_1781118557.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,098 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 100,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001961994-26-000017 · wk-form4_1777667409.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,792 F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,000 | $8.44 | $33,760.00 |
DisclosureSEC source: 0001961994-26-000013 · wk-form4_1775246752.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,681 F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 02:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 9,397 | $8.44 | $79,310.68 |
DisclosureSEC source: 0001961994-26-000009 · wk-form4_1772762934.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,681 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 02:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 44,834 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001961994-26-000009 · wk-form4_1772762934.xml · derivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,948 Underlying: Common Stock · 44,834 shares Expires 2033-03-02 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:33 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 116 | $8.15 | $945.40 |
DisclosureSEC source: 0001961994-26-000006 · wk-form4_1772573590.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,078 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,022 | $10.92 | $11,160.24 |
DisclosureSEC source: 0001961994-26-000003 · wk-form4_1770768441.xml · nonDerivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,194 F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 00:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Disposition to issuerCommon Stock | 8,655 | $10.92 | $94,512.60 |
DisclosureSEC source: 0001961994-26-000003 · wk-form4_1770768441.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,216 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 2,884 shares of common stock, which is less than the 11,539 shares previously reported on March 02, 2023 and June 09, 2023. Read SEC document |
| June 08, 2025 Filed Jun 10, 2025 20:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 464 | $6.63 | $3,076.32 |
DisclosureSEC source: 0001367644-25-000142 · wk-form4_1749586339.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,871 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001367644-25-000052 · wk-form4_1741637887.xml · derivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,114 Underlying: Common Stock · 62,500 shares Expires 2032-03-05 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000052 · wk-form4_1741637887.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,335 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 116 | $7.48 | $867.68 |
DisclosureSEC source: 0001367644-25-000032 · wk-form4_1741122397.xml · nonDerivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,835 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 382 | $7.48 | $2,857.36 |
DisclosureSEC source: 0001367644-25-000032 · wk-form4_1741122397.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,951 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:02 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 85 | $8.13 | $691.05 |
DisclosureSEC source: 0001367644-24-000120 · wk-form4_1720641753.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,333 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 20:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 464 | $6.19 | $2,872.16 |
DisclosureSEC source: 0001367644-24-000107 · wk-form4_1718136637.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,418 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001367644-24-000044 · wk-form4_1710537376.xml · derivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,614 Underlying: Common Stock · 125,000 shares Expires 2031-03-12 F1 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:43 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 137 | $3.39 | $464.43 |
DisclosureSEC source: 0001367644-24-000022 · wk-form4_1709595771.xml · nonDerivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,882 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:43 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 450 | $3.23 | $1,453.50 |
DisclosureSEC source: 0001367644-24-000022 · wk-form4_1709595771.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,019 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 01:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 105 | $2.74 | $287.70 |
DisclosureSEC source: 0001367644-24-000012 · wk-form4_1709083811.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,469 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 00:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 566 | $1.82 | $1,030.12 |
DisclosureSEC source: 0001367644-23-000190 · wk-form4_1700008050.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,574 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| July 08, 2023 Filed Jul 24, 2023 12:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000139 · wk-form4_1690201790.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,140 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 9,231 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001367644-23-000125 · wk-form4_1686705775.xml · derivative · entry 3 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,614 Underlying: Common Stock · 9,231 shares Expires 2030-06-08 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4 · balance_after: Represents the corrected number of securities owned due to a computational error in prior Form-4s Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 9,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000125 · wk-form4_1686705775.xml · nonDerivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,225 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000125 · wk-form4_1686705775.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,994 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock · Derivative | 2,308 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001367644-23-000069 · wf-form4_167814938664720.xml · derivative · entry 3 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,459 Underlying: Common Stock · 2,308 shares Expires 2030-03-01 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000069 · wf-form4_167814938664720.xml · nonDerivative · entry 2 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,378 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 1,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000069 · wf-form4_167814938664720.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,070 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:43 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 371 | $12.38 | $4,592.98 |
DisclosureSEC source: 0001367644-23-000059 · wf-form4_167778619560344.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,916 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 89 | $14.30 | $1,272.70 |
DisclosureSEC source: 0001367644-23-000036 · wf-form4_167754738229834.xml · nonDerivative · entry 1 Williams Paul Anthony · CIK 0001961994 · SVP, Products Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,287 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.